Mobile

A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sa...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002919-24

A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sandostatin® LAR® and pegvisomant, in acromegalic patients only partially responsive to somatostatin analog monotherapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to demonstrate the ability of a combination therapy with Sandostatin LAR and Cabergoline to reduce GH and IGF-I levels in acromegalic patients that are only partially responsive to Sandostatin LAR monotherapy. For the patients not responding to the combination after 5 months, a switch to the combination Sandostatin LAR and pegvisomant will be foreseen for a further 3 months therapy.

Critère d'inclusion

  • Acromegaly

Liens